Cargando…

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry

BACKGROUND: Ticagrelor is a P2Y(12) receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high‐dose aspirin. METHODS AND RESULTS: Patients in the acute coronary treatment and intervention outcomes network (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Basra, Sukhdeep S., Wang, Tracy Y., Simon, DaJuanicia N., Chiswell, Karen, Virani, Salim S., Alam, Mahboob, Nambi, Vijay, Denktas, Ali E., Deswal, Anita, Bozkurt, Biykem, Ballantyne, Christie M., Peterson, Eric D., Jneid, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220549/
https://www.ncbi.nlm.nih.gov/pubmed/29886424
http://dx.doi.org/10.1161/JAHA.117.008125
_version_ 1783368856359665664
author Basra, Sukhdeep S.
Wang, Tracy Y.
Simon, DaJuanicia N.
Chiswell, Karen
Virani, Salim S.
Alam, Mahboob
Nambi, Vijay
Denktas, Ali E.
Deswal, Anita
Bozkurt, Biykem
Ballantyne, Christie M.
Peterson, Eric D.
Jneid, Hani
author_facet Basra, Sukhdeep S.
Wang, Tracy Y.
Simon, DaJuanicia N.
Chiswell, Karen
Virani, Salim S.
Alam, Mahboob
Nambi, Vijay
Denktas, Ali E.
Deswal, Anita
Bozkurt, Biykem
Ballantyne, Christie M.
Peterson, Eric D.
Jneid, Hani
author_sort Basra, Sukhdeep S.
collection PubMed
description BACKGROUND: Ticagrelor is a P2Y(12) receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high‐dose aspirin. METHODS AND RESULTS: Patients in the acute coronary treatment and intervention outcomes network (ACTION) Registry‐Get With The Guidelines (GWTG) with acute myocardial infarction from October 2013 through December 2014 were included in the study (167 455 patients; 622 sites). We evaluated temporal trends in the prescription of P2Y(12) inhibitors, and identified factors associated with ticagrelor use at discharge. Among patients discharged on ticagrelor and aspirin (21 262 patients), we evaluated the temporal trends and independent factors associated with high‐dose aspirin prescription at discharge. Ticagrelor prescription at discharge increased significantly from 12% to 16.7% (P<0.0001). Decreases in prasugrel and clopidogrel use at discharge (15.7%–13.9% and 54.2%–51.1%, respectively, P<0.0001) were also observed. Independent factors associated with preferential ticagrelor prescription at discharge over clopidogrel included younger age, white race, home ticagrelor use, invasive management, and in‐hospital re‐infarction and stroke (P<0.0001 for all), whereas older age, female sex, prior stroke, home ticagrelor use, and in‐hospital stroke (P<0.0001 for all) were associated with preferential ticagrelor prescription at discharge over prasugrel. High‐dose aspirin was used in 3.1% of patients discharged on ticagrelor. Independent factors associated with high‐dose aspirin prescription at discharge included home aspirin use, diabetes mellitus, previous myocardial infarction, previous coronary artery bypass graft, ST‐segment–elevation myocardial infarction, cardiogenic shock, and geographic region (P=0.01). CONCLUSIONS: Our contemporary analysis shows a modest but significant increase in the use of ticagrelor and a high rate of adherence to the use of low‐dose aspirin at discharge.
format Online
Article
Text
id pubmed-6220549
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62205492018-11-15 Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry Basra, Sukhdeep S. Wang, Tracy Y. Simon, DaJuanicia N. Chiswell, Karen Virani, Salim S. Alam, Mahboob Nambi, Vijay Denktas, Ali E. Deswal, Anita Bozkurt, Biykem Ballantyne, Christie M. Peterson, Eric D. Jneid, Hani J Am Heart Assoc Original Research BACKGROUND: Ticagrelor is a P2Y(12) receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high‐dose aspirin. METHODS AND RESULTS: Patients in the acute coronary treatment and intervention outcomes network (ACTION) Registry‐Get With The Guidelines (GWTG) with acute myocardial infarction from October 2013 through December 2014 were included in the study (167 455 patients; 622 sites). We evaluated temporal trends in the prescription of P2Y(12) inhibitors, and identified factors associated with ticagrelor use at discharge. Among patients discharged on ticagrelor and aspirin (21 262 patients), we evaluated the temporal trends and independent factors associated with high‐dose aspirin prescription at discharge. Ticagrelor prescription at discharge increased significantly from 12% to 16.7% (P<0.0001). Decreases in prasugrel and clopidogrel use at discharge (15.7%–13.9% and 54.2%–51.1%, respectively, P<0.0001) were also observed. Independent factors associated with preferential ticagrelor prescription at discharge over clopidogrel included younger age, white race, home ticagrelor use, invasive management, and in‐hospital re‐infarction and stroke (P<0.0001 for all), whereas older age, female sex, prior stroke, home ticagrelor use, and in‐hospital stroke (P<0.0001 for all) were associated with preferential ticagrelor prescription at discharge over prasugrel. High‐dose aspirin was used in 3.1% of patients discharged on ticagrelor. Independent factors associated with high‐dose aspirin prescription at discharge included home aspirin use, diabetes mellitus, previous myocardial infarction, previous coronary artery bypass graft, ST‐segment–elevation myocardial infarction, cardiogenic shock, and geographic region (P=0.01). CONCLUSIONS: Our contemporary analysis shows a modest but significant increase in the use of ticagrelor and a high rate of adherence to the use of low‐dose aspirin at discharge. John Wiley and Sons Inc. 2018-06-09 /pmc/articles/PMC6220549/ /pubmed/29886424 http://dx.doi.org/10.1161/JAHA.117.008125 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Basra, Sukhdeep S.
Wang, Tracy Y.
Simon, DaJuanicia N.
Chiswell, Karen
Virani, Salim S.
Alam, Mahboob
Nambi, Vijay
Denktas, Ali E.
Deswal, Anita
Bozkurt, Biykem
Ballantyne, Christie M.
Peterson, Eric D.
Jneid, Hani
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
title Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
title_full Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
title_fullStr Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
title_full_unstemmed Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
title_short Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
title_sort ticagrelor use in acute myocardial infarction: insights from the national cardiovascular data registry
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220549/
https://www.ncbi.nlm.nih.gov/pubmed/29886424
http://dx.doi.org/10.1161/JAHA.117.008125
work_keys_str_mv AT basrasukhdeeps ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT wangtracyy ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT simondajuanician ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT chiswellkaren ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT viranisalims ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT alammahboob ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT nambivijay ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT denktasalie ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT deswalanita ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT bozkurtbiykem ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT ballantynechristiem ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT petersonericd ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry
AT jneidhani ticagreloruseinacutemyocardialinfarctioninsightsfromthenationalcardiovasculardataregistry